Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced presentations demonstrating the clinical impact of using its flagship metagenomic ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung ...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic ...

Objectives To describe the features and rates of emergency department (ED) presentations identified as related to violence against women (VAW) and of confirmed cases of family domestic violence (FDV) ...

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 Aurinia Pharmaceuticals Inc.